Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

HRTX holding history

Heron Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HRTX overviewAll 13F holders of HRTXFull Q2 2026 holdings

Shares (Q2 2026)
120,435
Value
$51.4K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of HRTX by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026120,435$51.4K<0.1%−2,480,555−95.4%ReducedHolders
Q1 20262,600,990$2.08M<0.1%−403,650−13.4%ReducedHolders
Q4 20253,004,640$3.91M<0.1%−83,852−2.7%ReducedHolders
Q3 20253,088,492$3.89M<0.1%−111,807−3.5%ReducedHolders
Q2 20253,200,299$6.62M<0.1%+214,102+7.2%AddedHolders
Q1 20252,986,197$6.57M<0.1%−737,509−19.8%ReducedHolders
Q4 20243,723,706$5.70M<0.1%−660,971−15.1%ReducedHolders
Q3 20244,384,677$8.73M<0.1%+521,302+13.5%AddedHolders
Q2 20243,863,375$13.5M<0.1%+1,168,329+43.4%AddedHolders
Q1 20242,695,046$7.47M<0.1%+1,404,049+108.8%AddedHolders
Q4 20231,290,997$2.19M<0.1%+1,045,724+426.4%AddedHolders
Q3 2023245,273$252.6K<0.1%−103,687−29.7%ReducedHolders
Q2 2023348,960$404.8K<0.1%−372,122−51.6%ReducedHolders
Q1 2023721,082$1.09M<0.1%−65,998−8.4%ReducedHolders
Q4 2022787,080$1.97M<0.1%−112,491−12.5%ReducedHolders
Q3 2022899,571$3.80M<0.1%−715,411−44.3%ReducedHolders
Q2 20221,614,982$4.51M<0.1%−419,247−20.6%ReducedHolders
Q1 20222,034,229$11.6M<0.1%+683,738+50.6%AddedHolders
Q4 20211,350,491$12.3M<0.1%−81,438−5.7%ReducedHolders
Q3 20211,431,929$15.3M<0.1%−532,221−27.1%ReducedHolders
Q2 20211,964,150$30.5M<0.1%−243,240−11.0%ReducedHolders
Q1 20212,207,390$35.8M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.